Board approves application to NSE for direct listing

Capital Market Events View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.6%Reaction day

₹96.60

prior close

₹96.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+6.2% vs market

Pharmaceuticals peers, median of 174sector+1.2%+5.4% vs sector

On the reaction day the stock moved 6.2 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.6+0.4+6.2+1.2+5.4

Next day

+6.6+2.1+4.5+3.1+3.5

+7.2+2.2+5.0+4.7+2.5

+6.6+2.9+3.8+4.7+2.0

+3.0pendingpending+3.4-0.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On October 24, 2026, the Board approved applying to NSE to list the company's entire issued and paid-up equity capital on the NSE Main Board under the direct listing route. The move needs NSE and other approvals and does not involve raising new capital.

Likely market impact

A successful NSE listing could widen investor access and support trading liquidity, but no new capital is being raised and approval is still required.